Identification |
Name: | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,sodium salt (1:2), (6R,7S)- |
Synonyms: | Apatef;Cefotan;Cefotetan disodium;Cefotetan sodium;Ceftenon;Cepan Darvilen;YM 09330;Yamatetan;(6R,7S)-4-((2-Carboxy-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl)carbamoyl)-1,3-dithietane-D2,a-malonamic Acid Disodium Salt;(6R,7S)-7-(4-(Carbamoylcarboxymethylene)-1,3-dithietane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid Disodium Salt; |
CAS: | 74356-00-6 |
EINECS: | 277-834-9 |
Molecular Formula: | C17H15N7Na2O8S4 |
Molecular Weight: | 619.59 |
InChI: | InChI=1/C17H17N7O8S4.2Na/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28;;/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30);;/q;2*+1/p-2/b12-6-;;/t13?,15-,17+;;/m1../s1 |
Molecular Structure: |
|
Properties |
Specification: |
1.Usage consumption: deep intramuscular injection, intravenous injection or intravenous infusion: Adult: Daily 1 ~ 6g, an equivalent sub-injection, 12 hours a time. Adults, the amount used every 12 hours with 1 ~ 2g. Daily maximum dose is limited to 6g. Children 40 ~ 60mg/kg · d, serious illness may be increased to 100mg/kg · d, 2 ~ 3 times.
2.Adverse effects of Disodium (7R)-7-[[4-(carbamoyl-carboxylato-methylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (74356-00-6) :1. To individual skin rash, itching, drug fever and other skin allergies. 2. Occasionally, as changes in blood, liver and kidney dysfunction, diarrhea and other adverse reactions; 3. A rare nausea, vomiting, shock and other adverse reactions.
|
Safety Data |
|
|